Pfizer inc (PFE) Sec Form 10K
Pfizer inc (NYSE: PFE) Sec Form 10K
Pfizer inc (PFE) PADCEV + Keytruda Cuts Risk of Recurrence or Death by Nearly 50% in Cisplatin-Eligible Muscle-Invasive Bladder Cancer
Pfizer inc (NYSE: PFE) FY 2026 Other Release
Pfizer inc (PFE) U.S. FDA Grants Full Approval to Pfizer’s BRAFTOVI Combination Regimen in First-Line Metastatic Colorectal Cancer
Pfizer inc (NYSE: PFE) FY 2026 Other Release
Pfizer inc (PFE) Pfizer Discussion at Healthcare Conference
Pfizer inc (NYSE: PFE) FY 2026 Corporate Conference
Pfizer inc (PFE) Pfizer’s BRAFTOVI Regimen Improves Progression-Free Survival in Metastatic Colorectal Cancer
Pfizer inc (NYSE: PFE) FY 2026 Other Release
AlphaGraphs
Key highlights from Pfizer’s (PFE) Q4 2025 earnings results
Pfizer Inc. (NYSE: PFE) reported its fourth quarter 2025 earnings results today. Revenues dipped 1% year-over-year to $17.6 billion. On an operational basis, revenues were…
Pfizer inc (PFE) Q2 2025 Earnings Call Transcript
Pfizer inc (NYSE: PFE) Q2 2025 Earnings Call dated Aug. 05, 2025 Corporate Participants: Francesca DeMartino — Chief Investor Relations Officer, Senior Vice President Albert…
Pfizer inc (PFE) Q3 2025 Earnings Call Transcript
Pfizer inc (NYSE: PFE) Q3 2025 Earnings Call dated Nov. 04, 2025 Corporate Participants: Francesca DeMartino — Chief Investor Relations Officer and Senior Vice President…
Market News
Key takeaways from Pfizer’s (PFE) Q3 2025 earnings report
Shares of Pfizer Inc. (NYSE: PFE) stayed green during midday trade on Tuesday following the company’s announcement of its third quarter 2025 earnings results. The…
AlphaGraphs
Key highlights from Pfizer’s (PFE) Q1 2025 earnings results
Pfizer Inc. (NYSE: PFE) reported its first quarter 2025 earnings results today. Revenues decreased 8% year-over-year to $13.7 billion. GAAP net income decreased 5% to…